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ABSTRACT 1 
Objective: To investigate trends in gabapentinoid prescribing in patients with osteoarthritis (OA). 2 
Methods: Patients aged 40 years and over with a new OA diagnosis recorded between 1995 and 3 
2015 were identified in the Clinical Practice Research Datalink and followed to first prescription of 4 
gabapentin or pregabalin, or other censoring event. We estimated the crude and age-standardised 5 
annual incidence rates of gabapentinoid prescribing, stratified by patient age, sex, geographical 6 
region, and time since OA diagnosis, and the proportion of prescriptions attributable to OA, or to 7 
other conditions representing licensed and unlicensed indications for a gabapentinoid prescription. 8 
Results: Of 383,680 newly diagnosed OA cases, 35,031 were prescribed at least one gabapentinoid. 9 
Irrespective of indication, the annual age-standardised incidence rate of first gabapentinoid 10 
prescriptions rose from 1.6 (95% CI: 1.3, 2.0) per 1,000 person-years in 2000, to 27.6 (26.7, 28.4) in 11 
2015, a trend seen across all ages and not explained by length of follow-up. Rates were higher 12 
among women, younger patients, and in Northern Ireland, Scotland and the North of England. 13 
Approximately 9% of first prescriptions could be attributed to OA, a further 13% to comorbid 14 
licensed or unlicensed indications. 15 
Conclusion: Gabapentinoid prescribing in patients with OA increased dramatically between 1995 16 
and 2015. In most cases, diagnostic codes for licensed or unlicensed indications were absent. 17 
Gabapentinoid prescribing may be attributable to OA in a significant proportion but evidence for 18 
their effectiveness in OA is lacking. Further research to investigate clinical decision making around 19 
prescribing these expensive and potentially harmful medicines is recommended. 20 
 21 
Keywords:  22 
Epidemiology; osteoarthritis; gabapentinoid; gabapentin; pregabalin 23 
 24 
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Introduction 1 
 2 
Over the last decade gabapentinoid (gabapentin and pregabalin) prescribing has increased 3 
substantially. In the United Kingdom (UK), prescriptions for gabapentin increased from fewer than 3 4 
million to 7.8 million, and for pregabalin from 2.1 million to 6.7 million between 2010 and 2016
1–4
, 5 
with similar patterns seen in other countries
5
. This increase in community prescribing within the UK 6 
may not only be accounted for by an increase in the number of gabapentinoids prescribed to 7 
existing users (likely due to a longer duration of therapy), but also by an increase in the number of 8 
patients prescribed them, with a recent study reporting that the rate of patients in the UK newly 9 
treated with either gabapentin or pregabalin has tripled between 2007 and 2017
6
.  10 
 In the UK, gabapentin and pregabalin are licensed for epilepsy and neuropathic pain, and pregabalin 11 
also for generalised anxiety disorder
7
. They have been recommended as first-line treatments for 12 
neuropathic pain since 2013, although evidence of efficacy is based largely on trials in post-herpetic 13 
neuralgia and painful diabetic neuropathy
8,9
. Limited evidence exists for efficacy of pregabalin in 14 
fibromyalgia
10
 but evidence in other painful conditions is lacking
11,12
. Nevertheless, ‘off-label’ 15 
gabapentinoid prescribing for painful conditions is common
5,6
. In 2017, more than 50% of UK 16 
gabapentinoid prescriptions were attributed to unlicensed indications
6
. Non-neuropathic, painful 17 
conditions may account for around 80% of unlicensed gabapentin and 50% of unlicensed pregabalin 18 
prescriptions
6
. This study explores the potential contribution of prescribing for osteoarthritis pain to 19 
the increase in gabapentinoid prescribing. 20 
Osteoarthritis (OA) is one of the most common painful musculoskeletal conditions worldwide
13
. OA 21 
guidelines internationally recommend a range of pharmacological treatments but not gabapentin or 22 
pregabalin
14–16
. Four small trials of pregabalin in OA have been published
17–20
. Whilst all identified a 23 
potential role for pregabalin in some patients with OA, there was no follow-up beyond 13 weeks. 24 
Despite this, anecdotal reports suggest that clinicians may prescribe gabapentinoids for “pain from 25 
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osteoarthritis”
5
. Concerns about perceived lack of effectiveness, adverse events, and safety concerns 1 
with recommended pharmacological treatments, poor access to non-pharmacological therapies and 2 
literature suggesting a neuropathic component to some OA pain may all contribute
21–28
. 3 
 4 
To our knowledge, no studies to date have investigated gabapentinoid prescribing rates specifically 5 
in patients with osteoarthritis, or explored what proportion of gabapentinoid use may be for 6 
osteoarthritis pain. Our analysis of national UK primary care electronic health record data addresses 7 
these evidence gaps. 8 
 9 
METHODS 10 
 11 
Data Source 12 
 13 
This was an observational epidemiological cohort study of data from the Clinical Practice Research 14 
Datalink (CPRD)’s GOLD dataset, a UK primary care database of routinely collected data from 15 
practices using the VISION software system. As of June 2017 the GOLD dataset collected data from 16 
693 contributing practices, with information from 14.2 million patients available, of which 2.8 million 17 
were active
29
. Anonymised information available includes patient demographics, consultations, 18 
diagnoses and prescriptions. Diagnoses and changes in management made in secondary care will 19 
also be included in the CPRD providing letters are communicated to the general practice and 20 
recorded appropriately. Equally, if a medication started in secondary care was continued as a repeat 21 
prescription by the general practitioner (who is largely responsible for a patient’s ongoing 22 
prescription), this would appear in the CPRD. Therefore, only one-off prescriptions issued in 23 
secondary care and not continued by the general practitioner may be missed by the CPRD. However, 24 
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as OA is a chronic condition and predominantly managed in the community, this would be a rare 1 
occurrence. 2 
Practices contributing data to the CPRD are representative of practices throughout the UK 3 
(approximately 7% of the UK population as of 2013)
30
, and the diagnostic coding, upon which 4 
research is carried out, has been validated for a number of diagnoses, including musculoskeletal 5 
conditions (although not including OA
31
). Our study was approved by the Independent Scientific 6 
Advisory Committee (ISAC; protocol 18_007R). No further ethical permission was required, due to 7 
the nature of the analysis on anonymised data. 8 
 9 
Study Design 10 
 11 
A cohort was assembled of patients with a new diagnosis of OA (first, index consultation) between 12 
1
st
 January 1995 and 31
st
 December 2015. A patient’s first diagnosis of OA was identified based upon 13 
the presence of an OA diagnostic Read code (‘higher level’ Read codes beginning N05, as used by 14 
prior studies
32,33
 and which have high positive predictive value). This code list includes both joint 15 
specific codes, and more generalised OA codes where the site is not specified. Those with an OA-16 
coded consultation or codes of hip or knee arthroplasty in the three years prior to the start of the 17 
study period were excluded; an efficient strategy for excluding prevalent cases of OA
34
. To reduce 18 
false positives during recruitment, and to ensure there was a temporal sequence between OA 19 
diagnosis and gabapentinoid prescription, we also excluded patients aged younger than 40 years at 20 
diagnosis as well as those patients who had received a gabapentinoid prescription in the three years 21 
prior to their index OA consultation, respectively. All OA codes used are available at 22 
www.keele.ac.uk/mrr/morbiditydefinitions/. 23 
 24 
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Patients were followed-up to the earliest of: gabapentinoid prescription, deregistering from their 1 
practice, death, practice no longer contributing data to the CPRD, or 31
st
 December 2015. In the 2 
event that the gabapentinoid prescription occurred on the same date as another censoring event, 3 
the prescription was included in analyses. 4 
 5 
Gabapentinoid Prescriptions 6 
 7 
Gabapentinoid prescriptions were identified by the presence of product codes in the cohort 8 
member’s healthcare records. These product codes have been used previously in the CPRD
35
, which 9 
were checked by an academic pain specialist and an academic general practitioner. 10 
 11 
Indications for Gabapentinoid Prescribing 12 
 13 
Within the UK general practitioners are encouraged to record a diagnostic code upon a new 14 
diagnosis or change in therapy
36
. However, unlike in some electronic health record systems in other 15 
countries, there is no direct link between each prescription and the indication for which it was 16 
issued. Therefore, in order to appreciate the proportion of first gabapentinoid prescriptions 17 
prescribed to patients with OA attributable to this condition, rather than to comorbidities, required 18 
identification of these comorbid conditions representing licensed and common unlicensed 19 
indications for gabapentinoid use. Possible indications for the gabapentinoids were identified using 20 
the British National Formulary (BNF), national guidelines issued by the National Institute for Health 21 
and Care Excellence (NICE), as well as by conducting scoping reviews of off-label gabapentinoid 22 
use
7,35,37–40
. Licensed indications are as mentioned above, and identified unlicensed indications 23 
included alcohol withdrawal, attention deficit disorder, bipolar disorder, complex regional pain 24 
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syndrome, fibromyalgia, menopausal hot flushes, migraine, panic disorder and restless legs 1 
syndrome. Code lists corresponding to these indications were sourced from a publically available 2 
clinical codes repository
41
, as well as by searching the CPRD bibliography
42
. 3 
 4 
Statistical Analyses 5 
 6 
For the period between 1995 and 2015 we calculated crude annual incidence rates, expressed per 7 
1,000 person-years, of first gabapentinoid prescription (irrespective of indication) among OA cohort 8 
members. Lexis expansion, which allows the progression of cohort members through more than one 9 
time-dependent variable simultaneously, was used to produce crude incidence rates stratified by 10 
age group (40-49, 50-59, 60-69, 70-79, 80+ years), gender, and geographical region of the general 11 
practice. Rates were also stratified by time since index OA consultation (<5, 5-9, 10-14, >15 years), 12 
and incidence rates were age-standardised using the cohort of patients present at mid-2015 as the 13 
reference population. 95% confidence intervals (CI) were calculated using Poisson regression. All 14 
analyses were conducted using SPSS version 24. 15 
 16 
Assuming an annual incidence of 1 per 1000, we would require at least 47,023 person-years of 17 
observation within each calendar year to detect a difference of 0.5 per 1000 person-years, at the 18 
95% confidence level with 80% power. Annual incidence rates after 2000 were based on person-time 19 
at risk greater than this although estimates prior to 2000 and from stratified analyses (e.g. by 20 
geographical region) would have lower precision. 21 
 22 
As per previous studies
6,43
, the indication for each gabapentinoid prescription was identified using 23 
the Read codes recorded at or around the time of prescription. In the primary analysis, prescriptions 24 
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were attributed to a condition providing the code was entered within the period from 14 days 1 
before to 90 days (-14 to +90) after the prescription date. Sensitivity analyses explored the effect of 2 
expanding this window to six months either side of prescription (-180 to +180) and then from one 3 
year before to six months after the gabapentinoid prescription date (-365 to +180). Six months 4 
following a patient’s first prescription was chosen as this has been used in a prior study of pregabalin 5 
use within UK primary care
43
. If patients had more than one consultation date for the same 6 
indication, the consultation closest to their first prescription date was chosen. As a result, whilst 7 
patients could have Read codes of numerous indications, they could only have one code for each 8 
condition. Consequently, attribution in the primary analysis would also occur in the following 9 
sensitivity analyses. We expressed the results of this analysis in mutually exclusive categories. 10 
Prescriptions were attributed to (in order of precedence): licensed indication, unlicensed indication 11 
(not including OA), OA, and finally the proportion of prescriptions that remained unattributable. 12 
 13 
RESULTS 14 
 15 
Our cohort comprised 383,680 patients newly diagnosed with OA between 1
st
 January 1995 and 31
st
 16 
December 2015 (baseline characteristics: Table 1). Median follow-up was 5.1 years (interquartile 17 
range (IQR): 2.3, 8.7), resulting in more than 2 million person-years of follow-up. 35,031 (9.1%) 18 
cohort members received a gabapentinoid prescription. First prescriptions were issued to patients 19 
with OA in all years of the study period, increasing from 2 in 1995, to 1,163 in 2005, and finally to 20 
3,954 in 2015 (available in supplementary table). Of the 35,031 prescriptions, 25,208 (72%) were 21 
gabapentin (most common dose: 300mg), the remainder pregabalin (most commonly 75mg 22 
capsules). 23 
 24 
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[Insert Table 1 Here] 1 
 2 
Incidence Rates 3 
 4 
The crude incidence rate of first gabapentinoid prescriptions in this cohort, irrespective of indication, 5 
increased throughout the course of the study period, rising from less than 1 per 1,000 person-years 6 
before 2000, to 9.5 (95% Confidence Interval: 9.0, 10.1) in 2005, and to 28.0 (27.2, 28.8) in 2014. The 7 
crude incidence rate remained fairly constant in 2015 (27.9 (27.1, 28.8) first prescriptions per 1,000 8 
person-years). Age-standardisation resulted in very similar rates and trend. Incidence rates were 9 
similar between age groups until 2005, but thereafter the incidence rate of first gabapentinoid 10 
prescription was consistently highest in those aged 40-49 years, and lowest in those aged ≥80 years 11 
(Table 2). The incidence of gabapentinoid prescribing increased throughout all strata of time since 12 
diagnosis, but was most pronounced in those who received their prescription within five years of 13 
their index consultation (available in supplementary table). 14 
 15 
[Insert Table 2 here] 16 
 17 
From the mid-2000s the age-standardised incidence rate of first prescriptions was higher in females 18 
than in males. Rates increased in females and males from 10.2 (9.5, 10.9) and 8.4 (8.0, 8.8) in 2005, 19 
through 18.8 (18.0, 19.6) and 15.2 (14.6, 15.9) in 2010, to 30.6 (29.5, 31.8) and 23.0 (22.0, 24.0) in 20 
2015, respectively. Throughout the study period, there was an increase in the age-sex standardised 21 
incidence rate of first gabapentinoid prescriptions in all 13 geographical regions of the CPRD. 22 
However, regions with a relatively high incidence compared to the remainder of the UK included 23 
Northern Ireland, Scotland and the North East and North West of England (Figure 1). 24 
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 1 
[Insert Figure 1 here]  2 
 3 
Attribution 4 
 5 
4,163 (11.9%) of the 35,031 patients prescribed a gabapentinoid had a code for a licensed indication 6 
within -14 to +90 days of the date of their first gabapentinoid prescription (Figure 2). This attribution 7 
was largely due to neuropathic pain (4,058 (97%), of which 1,291 were sciatica). As patients could 8 
have codes for more than one licensed indication, there were 4,176 codes given to this group of 9 
patients during this time. A further 543 (1.6%) first gabapentinoid prescriptions could be attributed 10 
to an unlicensed indication, of which fibromyalgia and restless legs syndrome were the most 11 
common. The proportion of first prescriptions attributed to a licensed or unlicensed indication was 12 
similar by gender, but slightly higher in older patients (10.8% in those aged 40-49 years, compared to 13 
14.8% in those aged over 80 years). 14 
 15 
3,303 (9.4%) of the 35,031 patients prescribed a gabapentinoid had a diagnostic code for OA entered 16 
within -14 to +90 days of the date of gabapentinoid prescription with no code for a licensed or 17 
unlicensed indication. Whilst the proportion of prescriptions attributed to OA was similar by patient 18 
gender and region, it was inversely proportional to age, with 17.1% of first prescriptions attributable 19 
to OA in those aged 40-49 years, compared to 7.9% in those aged 80 years or older. From 2001 20 
onwards, when there were more than 100 first prescriptions annually, the proportion of 21 
prescriptions attributed to OA remained fairly constant (9-11%). 22 
 23 
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A large proportion (27,022; 77.1%) of first gabapentinoid prescriptions remained unattributed to OA 1 
or a licensed or unlicensed indication in our primary analysis. Expansion of the time window studied 2 
from -14 days to +90 days from first gabapentinoid prescription, to six months either side of 3 
prescription, and finally to one year prior to six months after first prescription did increase 4 
attribution to licensed and unlicensed indications (from 13.4%, to 22.3% and then to 26.1%, 5 
respectively). Attribution to OA also increased in the same time periods, from 9.4%, to 22.9% and 6 
finally to 28.2%. However, 45.8% of first prescriptions remained unattributed even when allowing 7 
for relevant codes from -365 days to +180 days from the date of gabapentinoid prescription. 8 
Throughout all time windows studied the relative proportion of first gabapentinoid prescriptions 9 
attributed to OA compared to both licensed and unlicensed indications remained fairly constant. 10 
 11 
[Insert Figure 2 here] 12 
 13 
DISCUSSION 14 
 15 
Between 1995 and 2015 patients with OA have become increasingly likely to be prescribed a 16 
gabapentinoid. This increase in the incidence rate of gabapentinoid prescribing has been substantial 17 
and sustained. The age-standardised rate rose three-fold to 28 first gabapentinoid prescriptions per 18 
1,000 person-years between 2005 and 2015, and this is not explained by an increase in follow-up. 19 
Whilst this rising trend was evident for males and females of all ages and across all regions of the UK, 20 
those most likely to receive a gabapentinoid prescription were younger, female patients as well as 21 
those in Northern Ireland, Scotland and the North of England. 77% of first gabapentinoid 22 
prescriptions in this cohort of patients with OA did not have a relevant diagnostic code at or around 23 
the time of prescription. It is, therefore, difficult to establish precisely what proportion of 24 
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gabapentinoid prescriptions are for OA related pain or for other comorbidities. However, our 1 
analysis found that the proportion of first gabapentinoid prescriptions attributable to OA (9%), was 2 
similar to the proportion attributable to licensed or other common unlicensed indications combined 3 
(13%).  4 
 5 
Our study demonstrates a rising trend in gabapentinoid prescribing for patients with OA that mirrors 6 
the three-fold increase in prescribing across the general population
6
.  Although a large proportion of 7 
gabapentinoid prescriptions could not be attributed to any indication in the primary analysis, our 8 
findings suggest that prescribing for pain associated with OA, a condition for which gabapentinoids 9 
are unlicensed and have limited evidence of efficacy, has contributed to the overall rise in 10 
gabapentinoid prescribing. Comparison to prior literature provides further context to this. 11 
 12 
The attribution analysis in this study is similar to that of previous studies and therefore allows 13 
comparison. Like these prior studies, searching for codes within a narrow time window in relation to 14 
the gabapentinoid prescription date results in a large proportion of prescriptions unattributable to 15 
identified indications
43
, with a larger, more sensitive window resulting in fewer unattributed 16 
prescriptions
6,43
 (from 77.1% to 45.8% in our most sensitive analysis). However, this expansion 17 
requires the assumption that diagnostic codes entered weeks or months before or after prescription 18 
relate to its indication. Given this, the more conservative, narrow time window was used in our 19 
primary analysis. Furthermore, the use of mutually exclusive attribution categories, whereby 20 
patients with a prescription attributed to a licensed or unlicensed indication may also have had a 21 
code for OA in proximity to their prescription (but not attributed to OA) means that the presented 22 
contribution of OA is likely conservative. 23 
  24 
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Further comparison to prior literature demonstrates that the regional variation in prescribing rates is 1 
not exclusive to the gabapentinoids. For instance an English study of opioid consumption reported 2 
that nine out of the ten clinical commissioning groups with the highest opioid dose per head were in 3 
the North of England
44
. Another factor may be the influence of regional deprivation on prescribing 4 
rates. Whilst not specific to patients with OA, a UK based study of the prescribing of dependence 5 
forming medicines reported higher gabapentinoid prescribing across all conditions in areas with 6 
greater deprivation
35
. This report reported that the North East had low rates of long term 7 
gabapentinoid prescribing. This may not only reflect possible differences in prescribing in different 8 
conditions, but may demonstrate that this region has a high incidence of initiation of gabapentinoid 9 
prescribing, but short duration of use
35
. 10 
 11 
Our study has some limitations. First, although the CPRD is a nationwide dataset and representative 12 
of the UK as of the 2011 census
30
, the GOLD dataset relies on software found in only 9% of practices, 13 
mainly focussed in Manchester, Birmingham, London and the South of England
45
, which may affect 14 
generalisability. Second, our chosen definition of OA led to a smaller patient cohort and therefore 15 
the reported number of patients with OA prescribed a gabapentinoid is likely to be a conservative 16 
estimate. We included only incident OA, thus excluding a small number of patients who consulted 17 
for OA in the three years prior to the study period beginning, to allow the calculation of person-time 18 
as well as a patient’s time since diagnosis. We defined OA using diagnostic OA codes only, rather 19 
than including symptom codes such as ‘joint pain’, to minimise false positives. Using symptom codes 20 
may have given a cohort three times larger
34
. However, using diagnostic codes improved our ability 21 
to distinguish gabapentinoid prescriptions for OA from other indications, such as fibromyalgia and 22 
neuropathic pain, in the attribution analysis. Diagnostic codes are more likely to be used to record 23 
OA in older patients with more severe disease
46
, approximately 10 years after their initial 24 
presentation for joint pain
47
. This may explain the apparently counterintuitive finding of a higher 25 
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rate of prescribing in patients with a short time since diagnosis, given that, in clinical practice, one 1 
might expect clinicians to utilise recommended therapies first. 2 
 3 
Third, we were unable to attribute a large proportion of gabapentinoid prescriptions to any 4 
indication, leaving considerable uncertainty over the amount of prescribing specifically for the 5 
control of OA pain. A large proportion of prescriptions remained unattributed even in our most 6 
sensitive analysis, which may reflect a lack of diagnostic coding by primary care practitioners, 7 
therefore suggesting that the guidance on entering diagnostic codes upon a change in management 8 
is often not followed in practice. Other contributing factors to low attribution could be the use of 9 
codes by practitioners not included in our code lists and other unlicensed conditions not identified 10 
by the scoping reviews. For instance we have documented a declining trend in the recording of OA 11 
using diagnostic codes
48
, which may not only have reduced cohort recruitment in recent years, but 12 
also lead to an under-estimation of the proportion of gabapentinoid prescriptions attributable to OA 13 
during this time. A relatively stable proportion of first prescriptions were attributed to OA across the 14 
study period, a surprising finding, which is at odds with our hypotheses that rising gabapentinoid 15 
prescribing for patients with OA may be driven by growing concerns about currently recommended 16 
therapies, such as opioids, and by emerging evidence suggesting that OA pain may have a 17 
neuropathic component. A declining trend in the recording of OA in primary care could, in part, 18 
explain this. However, attribution of first prescriptions to licensed or unlicensed indications also 19 
remained fairly consistent throughout the study period, suggesting systematic under-recording of 20 
diagnoses by clinicians across all conditions. Another explanation may be that use of non-21 
recommended therapies to treat pain associated with OA pre-dates more recently emerging 22 
evidence and is driven primarily by a lack of effective treatment options. As the proportion of first 23 
gabapentinoid prescriptions attributed to OA relative to other indications, even in our sensitivity 24 
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analyses, remained fairly constant, we believe this provides evidence that, despite evidence of 1 
under-recording, osteoarthritis is an important cause of gabapentinoid prescription. 2 
 3 
OA is a common condition with a rising prevalence and therefore the potential impact of the 4 
observed rising trend in gabapentinoid prescribing for patients with OA is substantial both in terms 5 
of healthcare costs and potential harm to patients. In 2015, the UK National Health Service spent 6 
over £31 million on Gabapentin and £280 million on Pregabalin prescribing in England alone
2
. Given 7 
the lack of evidence to support the effectiveness of gabapentinoids for OA pain, more patients may 8 
be exposed to the potential harms of gabapentinoids without useful benefit. Side effects are 9 
commonly reported in patients using gabapentin or pregabalin. These include, among others, 10 
somnolence and dizziness
49
, which may be particularly problematic in patients with OA, as they may 11 
reduce exercise and activity, and increase the risk of falls. Patients with OA may also be prescribed 12 
other analgesics, including opioids, which may interact with the gabapentinoids resulting in a greater 13 
sedative effect, and increasing the risk of respiratory depression
50
. 14 
 15 
Further harm from gabapentinoid prescribing arises from their potential for misuse
49,51–53
, with 16 
increasing reports of both gabapentin and pregabalin being associated with overdoses and deaths in 17 
recent years. This has culminated in both gabapentinoids becoming controlled medications in the UK 18 
from 1
st
 April 2019
54
. Studies of gabapentinoid misuse have demonstrated that the risk of misuse in 19 
the general population appears low, with the highest risk being in populations with substance abuse 20 
disorders and prison inmates
49
. An association between overall gabapentinoid prescribing and 21 
gabapentinoid-related deaths has been reported
53
 and the high prevalence of OA has the potential 22 
to substantially increase the supply of prescribing gabapentinoids available for diversion in the 23 
community. Given the potential for harms and the high proportion of prescriptions that cannot be 24 
attributed to a licensed indication, understanding the determinants of off-label gabapentinoid 25 
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prescribing is important. We therefore encourage the replication of our analyses in other 1 
administrative and clinical patient electronic health record databases, particularly those with 2 
mandatory recording of indications for prescriptions, in conjunction with the investigation of the 3 
factors that may influence clinical decision making resulting in the prescription of a gabapentinoid. 4 
 5 
In conclusion, in the UK, there has been an increase in the likelihood of patients with OA being 6 
prescribed a gabapentinoid. Our analysis suggests that a proportion of gabapentinoid prescribing 7 
may be for pain associated with OA and therefore that prescribing for OA may have contributed to 8 
the general rise in gabapentinoid prescribing in the UK. Given the potential for harm and limited 9 
evidence of efficacy for their use for OA pain, gabapentinoid prescribing for this common, painful 10 
condition requires careful justification by clinicians. Further research to investigate clinical decision 11 
making around prescribing these medicines is recommended. 12 
 13 
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Table 1. Characteristics of Patients Newly Diagnosed with Osteoarthritis between 1995-2015 
Characteristic Total Patients with 
OA (n=383,680) 
Female gender, n (%) 234,159 (61.0) 
Age stratification, n (%)  
40-49yr 33,778 (8.8) 
50-59yr 88,120 (23.0) 
60-69yr 111,053 (28.9) 
70-79yr 95,506 (24.9) 
80+yr 55,223 (14.4) 
Geographical Region, n (%)  
North East 8,443 (2.2) 
North West 50,390 (13.1) 
Yorkshire & Humber 17,710 (4.6) 
East Midlands 17,535 (4.6) 
West Midlands 41,205 (10.7) 
East of England 34,664 (9.0) 
South West 33,674 (8.8) 
South Central 36,843 (9.6) 
London 28,124 (7.3) 
South East Coast 32,998 (8.6) 
Northern Ireland 10,817 (2.8) 
Scotland 31,547 (8.2) 
Wales 39,730 (10.4) 
Ethnicity, n (%)  
Not recorded 262,820 (68.5) 
White 115,872 (30.2) 
Other ethnic group 4,988 (1.3) 
Charlson Index of Comorbidity, n (%)  
HIV / AIDS 1 (0.0) 
Cancer 2,292 (0.6) 
Cerebrovascular diseases 1,328 (0.3) 
Chronic pulmonary diseases 3,672 (1.0) 
Coronary heart disease 1,037 (0.3) 
Dementia 590 (0.2) 
Diabetes mellitus 2,372 (0.6) 
Diabetes with complications 655 (0.2) 
Hemiplegia and paraplegia 54 (0.0) 
Metastatic tumour 148 (0.0) 
Mild liver disease 113 (0.0) 
Moderate or severe liver disease 27 (0.0) 
Myocardial infarction 1,097 (0.3) 
Peptic ulcer disease 743 (0.2) 
Peripheral vascular disease 871 (0.2) 
Renal disease 3,020 (0.8) 
Rheumatological disease 1,102 (0.3) 
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Table 2. Crude Incidence Rate of First Gabapentinoid Prescriptions by Patient Age Group, and Age-standardised Incidence Rate 
N.B. All incidence rates are displayed per 1,000 person-years. (IR: annual incidence rate, CI: confidence interval). Rates age-standardised against the cohort 
present in mid-2015 
Year 
Age Group 
Age Standardised 
40-49 Years 50-59 Years 60-69 Years 70-79 Years 80 Years and Over 
IR 95% CI IR 95% CI IR 95% CI IR 95% CI IR 95% CI IR 95% CI 
1995 0.00 (0.00, 10.83) 2.61 (0.32, 9.42) 0.00 (0.00, 3.46) 0.00 (0.00, 3.37) 0.00  (0.00, 6.33) 0.36 (0.00, 0.85) 
1996 1.03  (0.03, 5.75) 0.42 (0.01, 2.33) 0.30  (0.01, 1.65) 0.30  (0.01, 1.66) 0.00  (0.00, 1.84) 0.26  (0.01, 0.51) 
1997 0.67  (0.02, 3.71) 0.24 (0.01, 1.33) 0.00 (0.00, 0.62) 0.00 (0.00, 0.61) 0.00 (0.00, 1.02) 0.05 (0.00, 0.12) 
1998 0.52  (0.01, 2.89) 0.50 (0.10, 1.45) 0.23  (0.03, 0.83) 0.11 (0.00, 0.62) 0.19  (0.00, 1.05) 0.23  (0.07, 0.39) 
1999 0.43 (0.01, 2.41) 0.51 (0.14, 1.30) 0.71  (0.31, 1.40) 0.50 (0.18, 1.09) 0.28  (0.03, 1.02) 0.50  (0.29, 0.72) 
2000 4.62 (2.46, 7.90) 1.72 (1.00, 2.76) 1.21 (0.70, 1.93) 1.70 (1.10, 2.50) 1.59  (0.89, 2.62) 1.61 (1.27, 1.95) 
2001 4.02 (2.14, 6.88) 2.70 (1.85, 3.82) 2.63 (1.91, 3.53) 2.35 (1.68, 3.18) 2.88 (1.99, 4.02) 2.66 (2.25, 3.06) 
2002 4.55 (2.65, 7.28) 4.60 (3.54, 5.87) 4.66 (3.76, 5.72) 4.65 (3.77, 5.68) 3.62 (2.70, 4.75) 4.38  (3.90, 4.86) 
2003 7.55 (5.17, 10.67) 6.20 (5.06, 7.51) 5.66  (4.74, 6.70) 6.39  (5.43, 7.48) 5.12  (4.11, 6.31) 5.86 (5.35, 6.37) 
2004 6.72  (4.63, 9.44) 6.87 (5.77, 8.13) 7.19  (6.24, 8.24) 7.28 (6.33, 8.33) 6.23 (5.20, 7.40) 6.92 (6.41, 7.42) 
2005 10.38  (7.90, 13.39) 9.23 (8.03, 10.55) 9.80 (8.78, 10.90) 9.40 (8.40, 10.49) 9.46 (8.28, 10.75) 9.53 (8.98, 10.08) 
2006 13.57 (10.84, 16.78) 10.62 (9.39, 11.97) 9.57 (8.63, 10.59) 10.79 (9.78, 11.88) 9.43 (8.32, 10.64) 10.14  (9.61, 10.67) 
2007 13.44  (10.81, 16.53) 11.79 (10.53, 13.17) 12.35 (11.34, 13.42) 12.67  (11.63, 13.78) 11.24  (10.09, 12.49) 12.11 (11.56, 12.66) 
2008 18.01 (15.01, 21.43) 15.11 (13.71, 16.62) 13.34 (12.33, 14.40) 14.86  (13.78, 16.01) 11.99 (10.85, 13.21) 13.80 (13.24, 14.37) 
2009 20.05 (16.92, 23.59) 16.56 (15.11, 18.10) 15.38 (14.34, 16.48) 16.03  (14.94, 17.18) 13.39 (12.22, 14.63) 15.34 (14.77, 15.92) 
2010 28.95 (25.18, 33.12) 19.89 (18.31, 21.56) 17.50 (16.41, 18.64) 17.45 (16.32, 18.63) 14.73 (13.54, 16.01) 17.40  (16.80, 18.00) 
2011 30.26 (26.36, 34.58) 23.98  (22.24, 25.81) 19.10 (17.97, 20.28) 20.70 (19.47, 21.98) 16.22 (14.98, 17.53) 19.79 (19.15, 20.43) 
2012 36.53 (32.16, 41.32) 26.42 (24.59, 28.35) 19.32 (18.19, 20.50) 20.90 (19.68, 22.18) 16.86 (15.61, 18.17) 20.57 (19.93, 21.22) 
2013 40.28 (35.51, 45.51) 29.04 (27.07, 31.11) 22.16 (20.93, 23.45) 24.53 (23.20, 25.93) 21.11 (19.69, 22.59) 24.00 (23.29, 24.71) 
2014 48.49 (42.89, 54.63) 35.11 (32.84, 37.49) 24.50 (23.14, 25.93) 28.51 (27.02, 30.05) 23.78 (22.23, 25.41) 27.57 (26.78, 28.37) 
2015 44.06 (38.20, 50.55) 34.89  (32.46, 37.46) 26.90 (25.36, 28.51) 26.61 (25.05, 28.23) 23.85 (22.18, 25.61) 27.57 (26.71, 28.43) 
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Figure 1: Age-Sex Standardised Incidence Rate of Gabapentinoid Prescription, by Geographical 
Region 
Figure 2: Flow Chart of Attribution of First Gabapentinoid Prescriptions 
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Created onmapchart.net 
N.B. The East Midlands did not have data available for 2015, as no practices contributed data to the 
CPRD in this year.  
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Figure 2. Flow Chart of Attribution of First Gabapentinoid Prescriptions 
  
 
 
 
